The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
 
Taiki Hakozaki
No Relationships to Disclose
 
Corentin Richard
No Relationships to Disclose
 
Yusuke Okuma
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Lilly
Research Funding - Chugai Pharma (Inst); takeda (Inst)
 
Lisa Derosa
No Relationships to Disclose
 
Arielle Elkrief
No Relationships to Disclose
 
Laurence Zitvogel
Leadership - EverImmune
Honoraria - Lytix Biopharma; Transgene
Consulting or Advisory Role - Incyte; Lytix Biopharma
Research Funding - Innovate Biopharmaceuticals (Inst); Kaleido Biosciences; Lytix Biopharma; Roche; Transgene
Patents, Royalties, Other Intellectual Property - EverImmune
 
Bertrand Routy
No Relationships to Disclose
 
Yukio Hosomi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical